Memorial Sloan - Kettering Cancer Center is the famous Corporate Investor, which was founded in 1884. The venture was found in North America in United States. The leading representative office of defined Corporate Investor is situated in the New York.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2018.
The typical case for the fund is to invest in rounds with more than 10 participants. Despite the Memorial Sloan - Kettering Cancer Center, startups are often financed by The Column Group, OrbiMed, Med-Metrix. The meaningful sponsors for the fund in investment in the same round are The Column Group, Taiho Ventures, OrbiMed. In the next rounds fund is usually obtained by Topspin Partners, The Column Group, Taiho Ventures.
The current fund was established by Charlotte Augusta Gibbes, John Jacob Astor III.
Among the most popular portfolio startups of the fund, we may highlight Cota Healthcare. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Information Technology, Information Services.
Related Funds
| Fund Name | Location |
| Arnold Venture Group | Seattle, United States, Washington |
| Boulder Chamber | Boulder, Colorado, United States |
| Feibo | - |
| HO2 Partners | Dallas, Texas, United States |
| Linxi Venture Capital | Beijing, Beijing, China |
| Pennant Equity Partners | Marblehead, Massachusetts, United States |
| Social Sciences and Humanities Research Council | - |
| THTI Holdings | Beijing, Beijing, China |
| Xinwei Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Flare Therapeutics | $123M | 22 Mar 2023 | Cambridge, Massachusetts, United States | ||
Blue Note Therapeutics | $5M | 09 Sep 2021 | San Francisco, California, United States | ||
ORIC Pharmaceuticals | $50M | 21 Feb 2018 | South San Francisco, California, United States |
– Blue Note Therapeutics raised an additional $5.2m in Series A financing, bringing the company’s Series A financing to a total of $31m.
– The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
– The additional proceeds will strengthen Blue Note’s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Flare Therapeutics | $123M | 22 Mar 2023 | Cambridge, Massachusetts, United States | ||
Blue Note Therapeutics | $5M | 09 Sep 2021 | San Francisco, California, United States | ||
ORIC Pharmaceuticals | $50M | 21 Feb 2018 | South San Francisco, California, United States |
